<DOC>
	<DOCNO>NCT00799058</DOCNO>
	<brief_summary>A Multi-Center , Randomized , Double-Blind , PlaceboControlled Phase 3 Safety Effectiveness Trial Vaginal Matrix Ring Dapivirine Prevention HIV-1 Infection Women</brief_summary>
	<brief_title>A Safety Study Two Dapivirine ( TMC120 ) Vaginal Gels United States</brief_title>
	<detailed_description>IPM 020 double-blind , randomize , placebo-controlled Phase 3 expand safety trial conduct 5 research center United States among approximately 180 healthy , sexually active , HIV-negative woman ass safety Dapivirine Gel 4759 , 0.05 % 2.5g Dapivirine Gel 4789 , 0.05 % 2.5g compare HEC-based universal placebo .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Women 18 40 year age inclusive give write informed consent 2 . Available visit consent follow procedure schedule trial 3 . Healthy selfreported sexually active 4 . HIVnegative determine HIV test time enrollment 5 . Willing stable form contraception 6 . In absence use exogenous hormone ( ) , selfreported regular menstrual cycle 7 . Upon pelvic/speculum examination colposcopy enrollment visit , cervix vagina appear normal determined qualify research center staff 8 . Asymptomatic genital infection time enrollment 9 . Willing refrain use vaginal product object 14 day prior enrollment duration trial . 10 . Documentation abnormality Pap smear within 90 day prior randomization ; 11 . Willing answer acceptability adherence questionnaire throughout trial 12 . Willing refrain participation research trial duration trial 13 . Willing provide adequate locator information trial retention purpose reachable per local standard procedures 14 . Willing abstain follow criterion begin 48 hour prior trial visit : Vaginal intercourse Oral contact genitalia Internal vaginal wash Penetration vagina finger , sex toy , object , include medication 15 . Willing abstain follow 3 day biopsy procedure : Vaginal intercourse Oral contact genitalia Internal vaginal wash Penetration vagina finger , sex toy , object , include medication 1 . Currently pregnant last pregnancy outcome within 3 month prior screen 2 . Currently breastfeed , breastfed within 3 month prior screen 3 . Receipt investigational agent within 60 day prior screen 4 . Previously participate HIV vaccine trial 5 . Untreated urogenital infection within 2 week prior enrollment 6 . Presence abnormal physical finding vulva , vaginal wall cervix pelvic/speculum examination and/or colposcopy 7 . History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction 8 . Pap smear result screen require cryotherapy , biopsy treatment ( infection ) 9 . History symptomatic asymptomatic HSV2 10 . Any Grade 2 , 3 4 hematology , chemistry urinalysis laboratory abnormality baseline 11 . Unexplained , undiagnosed abnormal bleeding per vagina follow vaginal intercourse ; urogenital surgery within 90 day prior enrollment 12 . Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex 13 . Any serious acute , chronic progressive disease 14 . Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV-1 infection</keyword>
</DOC>